Intrinsic Medicine, Inc. (INRX)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	67.74M
Revenue (ttm)	n/a
Net Income (ttm)	-11.95M
Shares Out	11.29M
EPS (ttm)	-1.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About INRX

Intrinsic Medicine is a preclinical-stage therapeutics company leveraging synthetic biology-manufactured human identical milk oligosaccharide, or HiMO, molecules as new medicines to treat large patient populations underserved by current treatment options. In the first half of 2023, we plan to initiate a Phase 2 clinical trial under an approved protocol in Australia to test our lead drug candidate in over 400 patients with the constipation dominant form of irritable bowel syndrome, or IBS-C, which is estimated to affect approximately five millio...

• Industry: Health Care
• Sector: Pharmaceuticals
• Founded: 2018
• Employees: 8
• Stock Exchange: NASDAQ
• Ticker Symbol: INRX